DOI: 10.1002/ejoc.201101518

Synthesis of Difluoromethyl-Containing α-Acyloxycarboxamide Derivatives through a Passerini Reaction and Desulfonylation

Jingjing Wu,^[a] Wenwen Zhao,^[a] and Song Cao*^[a]

Keywords: Multicomponent reactions / Oxidation / Protecting groups / Fluorine / Synthetic methods

A series of difluoromethyl-containing a-acyloxycarboxamide derivatives were synthesized through a Passerini reaction of acids, aldehydes, and phenylsulfanyl-protected difluorinated isocyanide followed by *meta*-chloroperoxybenzoic acid me-

Introduction

The α-acyloxycarboxamide group is a functional motif which is found in many natural products and bioactive compounds.^[1] For example, azinomycins, which are natural products isolated from *Streptomyces griseofuscus*, can be used as antitumor agents.^[2] Compound I exhibits inhibitory activity for the RNase H function of HIV-1 reverse transcriptase,^[3] and compound II is reported to have herbicidal activity (Figure 1).^[4]



Figure 1. Examples of α -acyloxycarboxamide-containing drugs and agrochemicals.

 [a] Shanghai Key Laboratory of Chemical Biology, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China Fax: +86-21-64252603 E-mail: scao@ecust.edu.cn
 □ Supporting information for this article is available.

Supporting information for this article is available on the WWW under http://dx.doi.org/10.1002/ejoc.201101518.

diated oxidation and the removal of the phenylsulfonyl protecting group. The unexpected formation of deacylation products from the reaction between the Passerini products and Bu₃SnH/azobis(isobutyronitrile) was also reported.

The modification of molecules by the incorporation of fluorine-containing groups is widely used in drug discovery to alter the chemical, physical, and biological properties of the parent compounds.^[5] A survey of the literature indicates that only a few examples of the synthesis of fluorinated α acyloxycarboxamides are reported, and furthermore, most of these examples involve trifluoromethyl-containing compounds. Gulevich used trifluoromethyl-containing carbonyl compounds as one of the components to prepare trifluoromethyl a-acyloxycarboxamides through a Passerini reaction. These trifluoromethyl-containing Passerini products could be further transformed into trifluoromethyl depsipeptides for bioactivity screening.^[6a] Burger synthesized the trifluoromethyl-containing α -acyloxycarboxamides through a Passerini reaction of acids, aldehydes, and 2-isocyano-3,3,3-trifluoropropionate.[6b]

Recently, the introduction of the difluoromethyl group $(-CF_2H)$ into biologically active compounds^[7] has attracted much interest because of the unique physiological properties of this group.^[8] However, up until now, there has been no investigation concerning the synthesis of difluoromethyl α -acyloxycarboxamides. In continuation of our interest in



Scheme 1. Synthesis of difluoromethyl-containing α -acyloxycarboxamides through a Passerini reaction and desulfonylation.

1380



the synthesis of new difluoromethyl compounds,^[9] we intend to prepare difluoromethyl α -acyloxycarboxamides for bioactivity screening. Herein, we describe a new approach for the synthesis of difluoromethyl-containing α -acyloxycarboxamides through a Passerini reaction followed by (*m*-CPBA) *meta*-chloroperoxybenzoic acid mediated oxidation and the removal of the phenylsulfonyl group (Scheme 1).

Results and Discussion

Recently, we reported a general synthetic methodology for the construction of functionalized, small molecules bearing a terminal CF₂H group.^[10] A new difluoromethylene-containing building block, phenylsulfanyl-protected isocyanide **1**, was designed and used in the Ugi reaction for the synthesis of difluoromethyl-containing pseudopeptides.^[10a] Considering the Passerini reaction involves the reaction of aldehydes, carboxylic acids, and isocyanides and is the most efficient method for the preparation of α -acyloxycarboxamides,^[11] we used difluorinated isocyanide **1** as one component in a Passerini reaction to synthesize the difluoromethyl-containing α -acyloxycarboxamides. Thus, experiments using several different aldehydes, acids, and isocyanide **1** were carried out under solvent-free conditions (Table 1). To our delight, the reactions proceeded smoothly

Table 1. Synthesis of α -acyloxycarboxamides **2a–n** bearing a CF₂ unit through a Passerini reaction.^[a]

to give difluoromethylene compounds 2a-n in moderate to high yields. Aldehydes with electron-withdrawing groups attached to the aromatic ring afforded the Passerini products in higher yields and were, therefore, preferable for use in the reactions.

Generally, the Bu₃SnH/AIBN [azobis(isobutyronitrile)] system could be used to remove the PhS moiety from the difluoromethylene compounds to afford the difluomethyl compounds.^[12] Hence, we carried out the desulfanylation reaction of compound **2a** in the presence of 3 equiv. of Bu₃SnH and a catalytic amount of AIBN in refluxing toluene. Much to our surprise, the unexpected deacylation compound **5a** was obtained as a major product accompanied by a small amount of the desired desulfanylated product **4a** in a ratio of 9:1 (Scheme 2). However, in a survey of the literature, there is no report of the deacylation of an ester with Bu₃SnH. In addition, it was reported that the ester group remained intact, when Bu₃SnH was used to remove the PhS group in a phenylsulfanyl-containing ester.^[12c]

Subsequently, we selected Passerini products 2b-g to undergo the deacylation reaction to further examine the influence of R^1 and R^2 on the formation of the deacylation compounds (Table 2). The results indicate that the substituents (R^1 and R^2) in Passerini products 2a-g have a profound effect on the cleavage of the C–S or C–O bond. However, at the present stage, the effects could not be generalized,

R¹-COOH + R²-CHO 2a-n 1 \mathbb{R}^1 Yield [%][b] \mathbb{R}^2 Entry Compd. 1 Ph 2a Ph 84 2 80 **2b** CH₃ Ph 3 $4-CH_3C_6H_4$ 74 2cPh 4 2d Ph 3,4-(CH₃O)₂C₆H₃ 72 5 92 Ph 2e $4-FC_6H_4$ 2,3-F₂C₆H₃ 91 6 2f Ph 7 2g Ph 3-F-4-CF₃C₆H₃ 92 8 78 2h Ph PhCH₂ 9 73 2i Ph 4-CH₃OC₆H₄ 90 10 2j Ph 3-F-2-CH₃C₆H₃ 75 2k Ph $2\text{-}CH_3C_6H_4$ 11 12 21 Ph $3-BrC_6H_4$ 80 78 13 **2**m CH₃ $4-CH_3C_6H_4$ 14 2n CH₃ $4-FC_6H_4$ 91

[a] Reagents and conditions: acid (1 mmol), aldehyde (1 mmol), 1 (1 mmol), neat, room temp. [b] Isolated yield.



Scheme 2. Reaction of Passerini product 2a with Bu₃SnH/AIBN.

Table 2. Reaction of Passerini products 2a-g with Bu₃SnH/AIBN.^[a]

0 R ¹	R^2 H O O 2a-g	F F S	Ph Bu ₃ SnH, AIBN	O R ¹ HO	R^2	H F $H4a-gf$ F $F5a-f$
Entry	Compd.	\mathbb{R}^1	\mathbb{R}^2	Time	Yield [%][b]	
				[h]	4	5
1	2a	Ph	Ph	16	7	83 (5 a)
2	2b	CH_3	Ph	16	8	67 (5 a)
3	2c	Ph	$4-CH_3C_6H_4$	17	10	68 (5b)
4	2d	Ph	$3,4-(CH_3O)_2C_6H_3$	18	18	57 (5c)
5	2e	Ph	$4-FC_6H_4$	7	81	trace (5d)
6	2f	Ph	$2,3-F_2C_6H_3$	8	83	trace (5e)
7	2g	Ph	$3-F-4-CF_3C_6H_3$	8	85	trace (5f)

[a] Reagents and conditions: 2a-g (0.5 mmol), Bu_3SnH (1.5 mmol), AIBN (10 mol-%), toluene, reflux. [b] Isolated yield.



www.eurjoc.org

except that the presence of electron-withdrawing groups on the aromatic ring (\mathbb{R}^2) were unfavorable for the deacylation reaction and afforded desulfanylated products **4e–g** in good yields. Further investigations into the deacylating capacity of Bu₃SnH with different substrates and the mechanism of this reaction are in progress and will be reported in due course.

As the PhS moiety in some of the difluoromethylene Passerini products 2 could not be efficiently removed by Bu₃SnH/AIBN to afford the corresponding difluoromethyl compounds, we turned our efforts to find another synthetic route to the desired compounds. Based on the literature, difluorinated sulfones, sulfoxides, and sulfides can be used as efficient fluoroalkylating reagents to prepare difluoromethyl compounds, which then undergo cleavage of the sulfur-based functionalities.^[13] Accordingly, we assumed that the phenylsulfonyl group could be used as the protecting group instead of phenylsulfanyl group to obtain the difluoromethyl compounds. Generally, desulfonylation reactions proceed with reducing agents such as Na/Hg amalgam,^[14] SmI₂/HMPA (hexamethylphosphoramide),^[15] Mg/ HgCl₂,^[16] and Mg/HOAc/NaOAc.^[17] Moreover, the phenylsulfonyl-containing compounds can be conveniently prepared by the oxidation of phenylsulfanyl-containing compounds with *m*-chloroperbenzonic acid (*m*-CPBA).^[18] Hence, to overcome the drawbacks in the cleavage of some of the above-mentioned Passerini products with Bu₃SnH, we used m-CPBA to oxidize 2a-n to phenylsulfonyl difluoromethylene derivatives 3a-n. Among the reducing agents used for a desulfonylation reaction, reports show that Mg/ HOAc/NaOAc is an environmentally benign reaction system.^[17] Consequently, we removed the phenylsulfonyl group from 3a-n by employing the reducing agent Mg/HOAc/ NaOAc. Thus, we finally obtained the difluoromethyl products 4a-n successfully in high to excellent yields through this new and efficient approach (Scheme 3).



Scheme 3. Synthesis of α -acyloxycarboxamides **4a–n** containing a CF₂H group from difluorinated Passerini products **2a–n**.

Conclusions

In conclusion, we have reported a new and efficient approach to the synthesis of difluoromethyl-containing α -acyloxycarboxamide derivatives through a Passerini reaction followed by *m*-CPBA-mediated oxidation and removal of the phenylsulfonyl group. In addition, we disclosed an unexpected deacylation reaction with Bu₃SnH/AIBN for

some of the Passerini products. It might be a potentially new alternative for the cleavage of the C(O)–O single bond in an ester group.

Experimental Section

General Methods: All reagents were of analytic grade, obtained from commercial suppliers, and used without further purification. Melting points were measured in an open capillary with a Büchi melting point B-540 apparatus. ¹H NMR and ¹³C NMR spectroscopic data were recorded with a Bruker AM-400 spectrometer using TMS as an internal standard. The ¹⁹F NMR spectroscopic data were recorded with a Bruker AM-400 spectrometer, and the ¹⁹F NMR were measured with external CF₃CO₂H as the standard. High-resolution mass spectra (ESI) were recorded with a Micro-Mass LCTTM spectrometer. Column chromatography was carried out with Merck silica gel 60 (230–400 mesh).

Preparation of (1,1-Difluoro-2-isocyanoethyl)(phenyl)sulfane (1): Isocyanide **1** was synthesized according to literature procedures.^[10a]

General Procedure for the Synthesis of Compounds 2a–n: Isocyanide **1** (1 mmol) was added to a mixture of aldehyde (1 mmol) and carboxylic acid (1 mmol) at room temp. under solvent-free conditions. The mixture was stirred for 12 to 24 h (TLC). The crude residue was purified by chromatography to give the desired products **2a–n**.

2-[2,2-Difluoro-2-(phenylthio)ethylamino]-2-oxo-1-phenylethyl Benz-oate (2a): White solid (359 mg, 84%); m.p. 98.0–99.4 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.13 (d, *J* = 7.6 Hz, 2 H), 7.66–7.34 (m, 13 H), 6.61 (s, 1 H), 6.42 (s, 1 H), 3.98–3.84 (m, 2 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 168.6, 164.9, 136.4, 135.0, 133.8, 130.3, 129.9, 129.3, 129.0, 128.9, 128.7, 128.5, 127.6, 127.5 (t, ¹*J*_{C,F} = 274.9 Hz), 125.6, 75.8, 44.4 (t, ²*J*_{C,F} = 29.1 Hz) ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = -79.1 (dt, *J*_{F,F} = 214.1 Hz, *J*_{H,F} = 12.4 Hz), -79.7 (dt, *J*_{E,F} = 214.2 Hz, *J*_{H,F} = 12.5 Hz) ppm.

2-[2,2-Difluoro-2-(phenylthio)ethylamino]-2-oxo-1-phenylethyl Acetate (2b): White solid (292 mg, 80%); m.p. 88.7–90.0 °C. ¹H NMR (400 MHz, CDCl₃): δ = 7.6 (d, J = 7.6 Hz, 2 H), 7.47–7.37 (m, 8 H), 6.50 (t, J = 4.4 Hz, 1 H), 6.16 (s, 1 H), 3.94–3.85 (m, 2 H), 2.23 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 169.1, 168.5, 136.4, 135.0, 130.3, 129.3, 129.2, 128.9, 127.6, 127.5 (t, ¹ $J_{C,F}$ = 280.0 Hz), 125.6, 75.4, 44.4 (t, ² $J_{C,F}$ = 29.0 Hz), 21.0 ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = -79.1 (dt, $J_{F,F}$ = 208.0 Hz, $J_{H,F}$ = 12.4 Hz), -79.8 (dt, $J_{E,F}$ = 208.0 Hz, $J_{H,F}$ = 12.4 Hz) ppm.

2-[2,2-Difluoro-2-(phenylthio)ethylamino]-2-oxo-1-*p***-tolylethyl Benz-oate (2c):** White solid (326 mg, 74%); m.p. 127.5–128.2 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.14 (d, *J* = 7.2 Hz, 2 H), 7.65–7.36 (m, 10 H), 7.26–7.24 (m, 2 H), 6.69 (t, *J* = 6.0 Hz, 1 H), 6.40 (s, 1 H), 3.98–3.85 (m, 2 H), 2.38 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 168.6, 165.0, 139.2, 136.4, 133.8, 132.1, 130.2, 129.9, 129.6, 129.3, 129.2, 128.7, 127.6, 127.5 (t, ¹*J*_{C,F} = 279.9 Hz), 125.7, 75.8, 44.4 (t, ²*J*_{C,F} = 29.1 Hz), 21.3 ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = -79.3 (t, *J* = 12.4 Hz) ppm.

2-[2,2-Difluoro-2-(phenylthio)ethylamino]-1-(3,4-dimethoxyphenyl)-2-oxoethyl Benzoate (2d): White solid (351 mg, 72%); m.p. 138.4– 139.1 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.12 (d, *J* = 7.7 Hz, 2 H), 7.65–6.89 (m, 11 H), 6.55 (t, *J* = 5.8 Hz, 1 H), 6.37 (s, 1 H), 4.04–3.81 (m, 2 H), 3.91 (s, 3 H), 3.89 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 168.7, 165.0, 149.9, 149.3, 136.4, 133.7, 129.8, 129.3, 129.2, 128.9, 128.7, 127.5 (t, ¹*J*_{C,F} = 277.6 Hz), 127.4, 125.6, 120.6, 111.2, 110.8, 75.8, 56.0, 55.9, 44.4 (t, ²*J*_{C,F} =



29.3 Hz) ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = -79.3 (t, *J* = 12.4 Hz) ppm.

2-[2,2-Difluoro-2-(phenylthio)ethylamino]-1-(4-fluorophenyl)-2-oxoethyl Benzoate (2e): White solid (409 mg, 92%); m.p. 119.4– 120.3 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.13 (d, *J* = 7.3 Hz, 2 H), 7.67–7.09 (m, 12 H), 6.71 (t, *J* = 5.7 Hz, 1 H), 6.40 (s, 1 H), 4.04–3.81 (m, 2 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 168.4, 164.8, 163.2 (d, ¹*J*_{C,F} = 248.6 Hz), 136.4, 133.9, 131.0 (d, ⁴*J*_{C,F} = 3.3 Hz), 130.3, 129.8, 129.6 (d, ^{3'}*J*_{C,F} = 8.7 Hz), 129.3, 128.9, 128.8, 127.4 (t, ¹*J*_{C,F} = 279.8 Hz), 125.6, 115.9 (d, ^{2'}*J*_{C,F} = 21.9 Hz), 75.1, 44.5 (t, ²*J*_{C,F} = 29.0 Hz) ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = -79.4 (td, ¹*J* = 12.2 Hz, ²*J* = 3.9 Hz), -111.9 to -112.0 (m) ppm.

2-[2,2-Difluoro-2-(phenylthio)ethylamino]-1-(2,3-difluorophenyl)-2oxo-ethyl Benzoate (2f): White solid (421 mg, 91%); m.p. 111.8– 112.5 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.12 (d, *J* = 7.2 Hz, 2 H), 7.67–7.37 (m, 9 H), 7.26–7.13 (m, 2 H), 6.76 (t, *J* = 5.9 Hz, 1 H), 6.62 (s, 1 H), 4.05–3.86 (m, 2 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 167.4, 164.7, 150.6 (dd, ¹⁷*J*_{C,F} = 249.5 Hz, ²⁷*J*_{C,F} = 12.3 Hz), 149.0 (dd, ¹⁷*J*_{C,F} = 251.6 Hz, ²⁷*J*_{C,F} = 13.7 Hz), 136.4, 134.0, 130.3, 129.9, 129.3, 128.8, 128.6, 127.4 (t, ¹*J*_{C,F} = 280.1 Hz), 125.6, 125.1, 124.9, 124.8, 118.4 (d, ²⁷⁷*J*_{C,F} = 17.0 Hz), 70.3, 44.5 (t, ²*J*_{C,F} = 29.1 Hz) ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = -79.5 (t, *J* = 12.4 Hz), -136.9 to -137.0 (m), -140.7 (dt, ¹*J* = 20.8 Hz, ²*J* = 6.6 Hz) ppm.

2-[2,2-Difluoro-2-(phenylthio)ethylamino]-1-[3-fluoro-4-(trifluoro-methyl)phenyl]-2-oxoethyl Benzoate (2g): White solid (472 mg, 92%); m.p. 162.5–163.5 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.14 (d, *J* = 7.5 Hz, 2 H), 7.71–7.37 (m, 11 H), 6.71 (t, *J* = 5.6 Hz, 1 H), 6.44 (s, 1 H), 4.03–3.84 (m, 2 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 167.3, 164.4, 161.1, 141.6 (d, ^{3'}*J*_{C,F} = 8.5 Hz), 136.3, 134.3, 130.4, 129.9, 129.4, 128.9, 128.3, 127.7, 127.6, 127.3, 125.4, 122.9 (d, ^{4'}*J*_{C,F} = 3.9 Hz), 115.8 (d, ^{2'}*J*_{C,F} = 22.1 Hz), 74.3, 44.5 (t, ²*J*_{C,F} = 28.9 Hz) ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = -61.5 (d, *J* = 12.5 Hz), -79.6 (q, *J* = 12.7 Hz), -112.7 to -112.9 (m) ppm.

1-[2,2-Difluoro-2-(phenylthio)ethylamino]-1-oxo-3-phenylpropan-2-yl Benzoate (2h): White solid (344 mg, 78%); m.p. 81.3–82.6 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.02 (d, *J* = 7.5 Hz, 2 H), 7.65–7.22 (m, 13 H), 6.36 (t, *J* = 5.7 Hz, 1 H), 5.72 (t, *J* = 5.8 Hz, 1 H), 3.89–3.79 (m, 2 H), 3.42–3.32 (m, 2 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 169.3, 165.1, 136.3, 135.6, 133.8, 130.2, 129.8, 129.7, 129.3, 129.0, 128.7, 128.5, 127.3 (t, ¹*J*_{C,F} = 278.5 Hz), 127.1, 125.7, 74.7, 44.3 (t, ²*J*_{C,F} = 29.1 Hz), 37.7 ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = -79.1 (dt, *J*_{F,F} = 208.0 Hz, *J*_{H,F} = 9.5 Hz), -79.7 (dt, *J*_{E,F} = 213.6 Hz, *J*_{H,F} = 9.8 Hz) ppm.

2-[2,2-Difluoro-2-(phenylthio)ethylamino]-1-(4-methoxyphenyl)-2oxoethyl Benzoate (2i): White solid (334 mg, 73%); m.p. 109.7– 110.5 °C. ¹H NMR (400 MHz, CDCl₃): $\delta = 8.12$ (d, J = 7.2 Hz, 2 H), 7.65–7.36 (m, 10 H), 6.96–6.94 (m, 2 H), 6.66 (t, J = 6.0 Hz, 1 H), 6.38 (s, 1 H), 3.99–3.83 (m, 2 H), 3.82 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃): $\delta = 168.6$, 165.0, 160.3, 136.4, 133.7, 130.3, 129.9, 129.3, 129.2, 129.1, 128.7, 127.5 (t, ${}^{1}J_{C,F} = 279.9$ Hz), 127.2, 125.6, 114.3, 75.6, 55.3, 44.4 (t, ${}^{2}J_{C,F} = 29.0$ Hz) ppm. ¹⁹F NMR (376 MHz, CDCl₃): $\delta = -79.5$ (td, ${}^{1}J = 12.4$ Hz, ${}^{2}J = 2.0$ Hz) ppm.

2-[2,2-Difluoro-2-(phenylthio)ethylamino]-1-(3-fluoro-2-methylphenyl)-2-oxoethyl Benzoate (2j): White solid (413 mg, 90%); m.p. 97.9- 98.5 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.12 (d, *J* = 7.2 Hz, 2 H), 7.67–7.37 (m, 8 H), 7.31–7.20 (m, 2 H), 7.10–7.05 (m, 1 H), 6.63 (s, 1 H), 6.59 (t, *J* = 5.8 Hz, 1 H), 4.04–3.83 (m, 2 H), 2.47 (d, *J* = 1.9 Hz, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 168.3, 164.7, 161.4 (d, ^{1'}*J*_{C,F} = 244.8 Hz), 136.4, 136.0 (d, ^{3''}*J*_{C,F} = 4.1 Hz), 133.9, 130.3, 129.9, 129.4, 128.9, 128.8, 127.4 (t, ¹*J*_{C,F} = 280.1 Hz), 127.3 (d, ${}^{3'}J_{C,F}$ = 8.9 Hz), 125.6, 124.9 (d, ${}^{2''}J_{C,F}$ = 17.4 Hz), 123.6 (d, ${}^{4'}J_{C,F}$ = 3.2 Hz), 116.1 (d, ${}^{2'}J_{C,F}$ = 23.4 Hz), 73.1(d, ${}^{4''}J_{C,F}$ = 3.1 Hz), 44.4 (t, ${}^{2}J_{C,F}$ = 28.9 Hz), 10.8 (d, ${}^{3'''}J_{C,F}$ = 5.8 Hz) ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = -79.5 (q, J = 12.1 Hz), -114.8 to -114.9 (m) ppm.

2-[2,2-Difluoro-2-(phenylthio)ethylamino]-2-oxo-1-*o***-tolylethyl Benzoate (2k):** White solid (331 mg, 75%); m.p. 86.3–87.3 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.15 (d, *J* = 7.7 Hz, 2 H), 7.65–7.27 (m, 12 H), 6.74 (t, *J* = 6.0 Hz, 1 H), 6.69 (s, 1 H), 4.01–3.86 (m, 2 H), 2.60 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 168.9, 166.0, 137.4, 136.4, 133.8, 131.2, 130.3, 130.1, 129.9, 129.4, 129.1, 128.7, 128.5, 128.2, 127.6 (t, ¹*J*_{C,F} = 280.1 Hz), 126.5, 125.7, 73.7, 44.5 (t, ²*J*_{C,F} = 28.8 Hz), 19.6 ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = -79.0 to -79.2 (m) ppm.

1-(3-BromophenyI)-2-[2,2-difluoro-2-(phenylthio)ethylamino]-2-oxoethyl Benzoate (2l): White solid (405 mg, 80%); m.p. 84.3–85.6 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.14 (d, *J* = 7.6 Hz, 2 H), 7.76– 7.29 (m, 12 H), 6.75 (t, *J* = 6.0 Hz, 1 H), 6.38 (s, 1 H), 4.00–3.82 (m, 2 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 168.1, 164.7, 137.2, 136.9, 136.4, 134.0, 132.4, 130.5, 130.4, 129.9, 129.3, 128.8, 128.7, 127.5 (t, ¹*J*_{C,F} = 280.6 Hz), 126.3, 125.6, 122.9, 74.9, 44.5 (t, ²*J*_{C,F} = 29.2 Hz) ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = -78.9 (dt, *J*_{F,F} = 208.2 Hz, *J*_{H,F} = 12.2 Hz), -79.5 (dt, *J*_{F,F} = 208.2 Hz, *J*_{H,F} = 9.8 Hz) ppm.

2-[2,2-Difluoro-2-(phenylthio)ethylamino]-2-oxo-1-*p***-tolylethyl** Acetate (2m): White solid (295 mg, 78%); m.p. 96.4–97.6 °C. ¹H NMR (400 MHz, CDCl₃): δ = 7.59 (d, J = 7.5 Hz, 2 H), 7.48–7.20 (m, 7 H), 6.53 (t, J = 6.0 Hz, 1 H), 6.13 (s, 1 H), 3.93–3.84 (m, 2 H), 2.37 (s, 3 H), 2.20 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 169.2, 168.7, 139.2, 136.4, 132.1, 130.2, 129.5, 129.3, 127.6, 127.5 (t, ¹ $J_{C,F}$ = 282.5 Hz), 125.7, 75.3, 44.4 (t, ² $J_{C,F}$ = 29.0 Hz), 21.2, 21.0 ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = -79.0 (dt, $J_{F,F}$ = 208.4 Hz, $J_{H,F}$ = 12.3 Hz), -79.6 (dt, $J_{F,F}$ = 208.4 Hz, $J_{H,F}$ = 12.3 Hz) ppm.

2-[2,2-Difluoro-2-(phenylthio)ethylamino]-1-(4-fluorophenyl)-2-oxoeth-yl Acetate (2n): White solid (348 mg, 91%); m.p. 72.9–74.1 °C. ¹H NMR (400 MHz, CDCl₃): δ = 7.57 (d, J = 7.5 Hz, 2 H), 7.49– 7.05 (m, 7 H), 6.79 (t, J = 6.0 Hz, 1 H), 6.14 (s, 1 H), 3.92–3.83 (m, 2 H), 2.19 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 169.2, 168.6, 163.1 (d, ^{1'} $J_{C,F}$ = 248.5 Hz), 136.4, 131.1 (d, ^{4'} $J_{C,F}$ = 3.2 Hz), 130.3, 129.6 (d, ^{3'} $J_{C,F}$ = 8.5 Hz), 129.3, 127.4 (t, ¹ $J_{C,F}$ = 271.1 Hz), 125.6, 115.8 (d, ^{2'} $J_{C,F}$ = 21.8 Hz), 74.7, 44.5 (t, ² $J_{C,F}$ = 28.8 Hz), 20.9 ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = –79.3 (td, ¹J = 12.5 Hz, ²J = 4.4 Hz), –111.9 to –112.0 (m) ppm.

General Procedure for the Synthesis of Compounds 3a–n: To a solution of Passerini products 2a-n (0.7 mmol) in CH₂Cl₂ was added *m*-CPBA (2.1 mmol) at 0 °C. The ice bath was removed, and the reaction mixture was stirred at room temp. for 24–48 h (TLC). A saturated aqueous solution of Na₂S₂O₃ was added to quench the reaction. The layers were separated, and the aqueous phase was extracted with CH₂Cl₂. The combined organic phases were washed with saturated NaHCO₃ and brine, dried with Na₂SO₄, filtered, and concentrated to get the crude product which was purified by chromatography to afford products **3a–n**.

2-[2,2-Difluoro-2-(phenylsulfonyl)ethylamino]-2-oxo-1-phenylethyl Benzoate (3a): White solid (289 mg, 90%); m.p. 126.1–127.6 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.19 (d, *J* = 7.8 Hz, 2 H), 7.96–7.38 (m, 13 H), 7.08 (t, *J* = 5.5 Hz, 1 H), 6.43 (s, 1 H), 4.36–4.26 (m, 2 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 168.9, 164.7, 136.0, 135.1, 133.8, 131.4, 130.8, 130.0, 129.6, 129.3, 128.9, 128.7, 127.4, 124.9, 120.2 (t, ¹*J*_{C,F} = 289.7 Hz), 75.8, 38.4 (t, ²*J*_{C,F} =

FULL PAPER

25.9 Hz) ppm. ¹⁹F NMR (376 MHz, CDCl₃): $\delta = -107.7$ (t, J = 12.4 Hz) ppm.

2-[2,2-Difluoro-2-(phenylsulfonyl)ethylamino]-2-oxo-1-phenylethyl Acetate (3b): White solid (253 mg, 91%.); m.p. 107.8–108.9 °C. ¹H NMR (400 MHz, CDCl₃): δ = 7.98 (d, *J* = 7.7 Hz, 2 H), 7.84–7.39 (m, 8 H), 6.91 (t, *J* = 5.6 Hz, 1 H), 6.19 (s, 1 H), 4.38–4.15 (m, 2 H), 2.25 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 169.1, 168.9, 135.9, 134.9, 131.6, 130.8, 129.6, 129.2, 128.8, 127.4, 120.2 (t, ¹*J*_{C,F} = 288.7 Hz), 75.3, 38.4 (t, ²*J*_{C,F} = 25.9 Hz), 20.9 ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = –107.0 (dt, *J*_{E,F} = 235.1 Hz, *J*_{H,F} = 11.7 Hz), –108.2 (dt, *J*_{E,F} = 235.1 Hz, *J*_{H,F} = 13.2 Hz) ppm.

2-[2,2-Difluoro-2-(phenylsulfonyl)ethylamino]-2-oxo-1-*p***-tolylethyl Benzoate (3c):** White solid (301 mg, 91%.); m.p. 84.8–85.6 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.18 (d, *J* = 7.5 Hz, 2 H), 7.96–7.22 (m, 12 H), 7.07 (t, *J* = 6.0 Hz, 1 H), 6.40 (s, 1 H), 4.34–4.25 (m, 2 H), 2.37 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 169.1, 164.8, 139.2, 135.9, 133.7, 132.2, 131.6, 130.7, 130.0, 129.6, 129.5, 129.1, 128.6, 127.4, 120.3 (t, ¹*J*_{C,F} = 289.9 Hz), 75.8, 38.4 (t, ²*J*_{C,F} = 25.3 Hz), 21.3 ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = –107.6 (td, ¹*J* = 12.8 Hz, ²*J* = 2.2 Hz) ppm.

2-[2,2-Difluoro-2-(phenylsulfonyl)ethylamino]-1-(3,4-dimethoxyphenyl)-2-oxoethyl Benzoate (3d): White solid (327 mg, 90%); m.p. 121.3–122.3 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.17–8.15 (m, 2 H), 7.95–7.09 (m, 10 H), 7.05 (t, J = 6.2 Hz, 1 H), 6.90–6.88 (m, 1 H), 6.37 (s, 1 H), 4.42–4.19 (m, 2 H), 3.91 (s, 3 H), 3.89 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 169.1, 164.9, 149.9, 149.3, 136.0, 133.7, 131.6, 130.7, 129.9, 129.6, 129.1, 128.6, 127.5, 120.5, 120.3 (t, ¹ $_{J_{C,F}}$ = 290.4 Hz), 111.2, 110.7, 75.7, 56.0, 55.9, 38.5 (t, ² $_{J_{C,F}}$ = 25.7 Hz) ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = -107.1 (dt, $J_{F,F}$ = 235.5 Hz, $J_{H,F}$ = 12.4 Hz), -107.8 (dt, $J_{F,F}$ = 235.5 Hz, $J_{H,F}$ = 12.5 Hz) ppm.

2-[2,2-Difluoro-2-(phenylsulfonyl)ethylamino]-1-(4-fluorophenyl)-2oxoethyl Benzoate (3e): White solid (307 mg, 92%); m.p. 125.1– 126.6 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.17 (d, J = 7.5 Hz, 2 H), 7.96–7.49 (m, 10 H), 7.13–709 (m, 3 H), 6.41 (s, 1 H), 4.36– 4.25(m, 2 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 168.8, 164.7, 163.2 (d, ^{1'} $J_{C,F}$ = 248.5 Hz), 136.0, 133.9, 131.5, 131.1, 130.7, 129.9, 129.6, 129.4 (d, ^{3'} $J_{C,F}$ = 8.5 Hz), 128.8, 128.7, 120.3 (t, ¹ $J_{C,F}$ = 289.8 Hz), 115.9 (d, ^{2'} $J_{C,F}$ = 21.8 Hz), 75.1, 38.5 (t, ² $J_{C,F}$ = 25.6 Hz) ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = –107.2 (dt, $J_{F,F}$ = 235.3 Hz, $J_{H,F}$ = 12.4 Hz), –107.9 (dt, $J_{F,F}$ = 235.2 Hz, $J_{H,F}$ = 12.4 Hz), –112.0 to –112.1 (m) ppm.

2-[2,2-Difluoro-2-(phenylsulfonyl)ethylamino]-1-(2,3-difluorophenyl)-2-oxoethyl Benzoate (3f): White solid (315 mg, 91%); m.p. 137.7–139.0 °C. ¹H NMR (400 MHz, CDCl₃): $\delta = 8.16$ (d, J = 7.2 Hz, 2 H), 7.99–7.49 (m, 8 H), 7.35 (t, J = 7.0 Hz, 1 H), 7.25–7.12 (m, 3 H), 6.63 (s, 1 H), 4.45–4.22 (m, 2 H) ppm. ¹³C NMR (100 MHz, CDCl₃): $\delta = 167.8$, 164.6, 150.6 (dd, ^{1'} $J_{C,F} = 249.4$ Hz, ^{2''} $J_{C,F} = 12.4$ Hz), 149.1 (dd, ^{1''} $J_{C,F} = 251.4$ Hz, ^{2''} $J_{C,F} = 13.0$ Hz), 136.0, 134.0, 131.6, 130.8, 130.0, 129.6, 128.7, 128.6, 125.1 (d, ^{3'} $J_{C,F} = 10.5$ Hz), 124.8, 124.5, 120.2 (t, ¹ $J_{C,F} = 291.0$ Hz), 118.4 (d, ^{2'} $J_{C,F} = 17.1$ Hz), 70.4, 38.5 (t, ² $J_{C,F} = 234.9$ Hz, $J_{H,F} = 12.8$ Hz), -108.0 (dt, $J_{F,F} = 234.6$ Hz, $J_{H,F} = 12.9$ Hz), -136.9 to -137.0 (m), -140.6 (d, J = 20.7 Hz) ppm.

2-[2,2-Difluoro-2-(phenylsulfonyl)ethylamino]-1-[3-fluoro-4-(trifluoro-methyl)phenyl]-2-oxoethyl Benzoate (3g): White solid (339 mg, 89%); m.p. 117.6–118.5 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.20 (d, *J* = 7.6 Hz, 2 H), 7.97–7.45 (m, 11 H), 7.24 (t, *J* = 5.9 Hz, 1 H), 6.44 (s, 1 H), 4.42–4.22 (m, 2 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 167.7, 164.4, 161.1, 141.7 (d, ^{3'}*J*_{C,F} = 7.0 Hz), 136.1,

134.2, 131.3, 130.7, 130.0, 129.6, 128.9, 128.3, 127.7, 127.6, 123.0 (d, ${}^{4'}J_{C,F} = 3.8$ Hz), 120.2 (t, ${}^{1}J_{C,F} = 258.3$ Hz), 115.7 (d, ${}^{2'}J_{C,F} = 22.0$ Hz), 74.3, 38.6 (t, ${}^{2}J_{C,F} = 26.3$ Hz) ppm. 19 F NMR (376 MHz, CDCl₃): $\delta = -61.5$ (d, J = 12.6 Hz), -107.1 (dt, $J_{F,F} = 235.7$ Hz, $J_{H,F} = 12.3$ Hz), -107.9 (dt, $J_{F,F} = 235.7$ Hz, $J_{H,F} = 12.6$ Hz), -112.7 to -112.9 (m) ppm.

1-[2,2-Difluoro-2-(phenylsulfonyl)ethylamino]-1-oxo-3-phenylpropan-2-yl Benzoate (3h): White solid (301 mg, 91%); m.p. 60.1–61.2 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.05–8.03 (m, 2 H), 7.89–7.22 (m, 13 H), 6.96 (t, *J* = 6.3 Hz, 1 H), 5.72 (dd, ¹*J* = 6.6 Hz, ²*J* = 5.0 Hz, 1 H),4.24–4.10 (m, 2 H), 3.41–3.30 (m, 2 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 169.9, 165.2, 135.9, 135.7, 133.7, 131.6, 130.7, 129.8, 129.7, 129.5, 129.0, 128.6, 128.5, 127.0, 120.4 (t, ¹*J*_{C,F} = 289.8 Hz), 74.7, 38.1 (t, ²*J*_{C,F} = 24.4 Hz), 37.8 ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = –79.1 (td, ¹*J* = 13.5 Hz, ²*J* = 4.3 Hz) ppm.

2-[2,2-Difluoro-2-(phenylsulfonyl)ethylamino]-1-(4-methoxyphenyl)-2-oxoethyl Benzoate (3i): White solid (305 mg, 89%); m.p. 140.3– 141.5 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.16 (d, *J* = 7.8 Hz, 2 H), 7.95–7.47 (m, 10 H), 7.11 (t, *J* = 6.1 Hz, 1 H), 6.95–6.93 (m, 2 H), 6.38 (s, 1 H), 4.35–4.23 (m, 2 H), 3.81 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 169.3, 164.9, 160.3, 135.9, 133.7, 131.6, 130.7, 129.9, 129.6, 129.1, 129.0, 128.6, 127.3, 120.4 (t, ¹*J*_{C,F} = 289.8 Hz), 114.3, 75.6, 55.3, 38.4 (t, ²*J*_{C,F} = 25.1 Hz) ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = –107.2 (dt, *J*_{E,F} = 233.8 Hz, *J*_{H,F} = 12.3 Hz), –107.9 (dt, *J*_{E,F} = 227.8 Hz, *J*_{H,F} = 12.9 Hz) ppm.

2-[2,2-Difluoro-2-(phenylsulfonyl)ethylamino]-1-(3-fluoro-2-methylphenyl)-2-oxoethyl Benzoate (3j): White solid (309 mg, 90%); m.p. 142.5–143.8 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.18–8.15 (m, 2 H), 7.97–7.19 (m, 10 H), 7.13 (t, J = 6.1 Hz, 1 H), 7.08–7.04 (m, 1 H), 6.65 (s, 1 H), 4.39–4.24 (m, 2 H), 2.48 (d, J = 1.9 Hz, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 168.7, 164.7, 161.4 (d, ¹⁷ $J_{C,F}$ = 244.5 Hz), 136.2 (d, ^{3''} $J_{C,F}$ = 4.2 Hz), 136.0, 133.9, 131.5, 130.7, 129.9, 129.6, 128.8, 128.7, 127.3 (d, ^{3'} $J_{C,F}$ = 8.9 Hz), 124.9 (d, ^{2''} $J_{C,F}$ = 17.6 Hz), 123.4 (d, ^{4'} $J_{C,F}$ = 3.4 Hz), 120.3 (t, ¹ $J_{C,F}$ = 290.6 Hz), 116.0 (d, ^{2'} $J_{C,F}$ = 23.4 Hz), 73.0 (d, ^{4''} $J_{C,F}$ = 2.9 Hz), 38.4 (t, ² $J_{C,F}$ = 25.5 Hz), 10.7 (d, ^{3'''} $J_{C,F}$ = 5.7 Hz) ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = -107.0 (dt, $J_{F,F}$ = 234.8 Hz, $J_{H,F}$ = 12.1 Hz), -108.0 (dt, $J_{F,F}$ = 234.7 Hz, $J_{H,F}$ = 12.7 Hz), -115.0 to -115.1 (m) ppm.

2-[2,2-Difluoro-2-(phenylsulfonyl)ethylamino]-2-oxo-1-*o***-tolylethyl Benzoate (3k):** White solid (295 mg, 89%); m.p. 143.8–144.7 °C. ¹H NMR (400 MHz, CDCl₃): $\delta = 8.17$ (d, J = 7.6 Hz, 2 H), 7.97–7.25 (m, 12 H), 7.04 (t, J = 5.9 Hz, 1 H), 6.66 (s, 1 H), 4.38–4.24 (m, 2 H), 2.59 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃): $\delta = 169.2$, 164.8, 137.3, 136.0, 133.8, 133.7, 131.6, 131.1, 130.8, 129.9, 129.6, 129.3, 129.0, 128.7, 127.7, 126.4, 120.3 (t, ¹ $J_{C,F} = 290.1$ Hz), 73.4, 38.4 (t, ² $J_{C,F} = 25.3$ Hz), 19.6 ppm. ¹⁹F NMR (376 MHz, CDCl₃): $\delta = -107.1$ (dt, $J_{F,F} = 235.6$ Hz, $J_{H,F} = 12.7$ Hz), -107.9 (dt, $J_{F,F} = 235.3$ Hz, $J_{H,F} = 12.4$ Hz) ppm.

1-(3-Bromophenyl)-2-[2,2-difluoro-2-(phenylsulfonyl)ethylamino]-2-oxoethyl Benzoate (3l): White solid (339 mg, 90%); m.p. 136.2–137.5 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.18 (d, *J* = 7.3 Hz, 2 H), 7.97–7.19 (m, 12 H), 7.18 (t, *J* = 6.1 Hz, 1 H), 6.38 (s, 1 H), 4.35–4.22 (m, 2 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 168.4, 164.6, 137.3, 136.0, 134.0, 132.4, 131.5, 130.8, 130.4, 130.3, 130.0, 129.6, 128.8, 128.7, 126.2, 122.8, 120.2 (t, ¹*J*_{C,F} = 290.1 Hz), 75.0, 38.5 (t, ²*J*_{C,F} = 25.8 Hz) ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = -107.2 (dt, *J*_{F,F} = 235.6 Hz, *J*_{H,F} = 12.4 Hz), -107.9 (dt, *J*_{F,F} = 235.7 Hz, *J*_{H,F} = 12.4 Hz) ppm.

2-[2,2-Difluoro-2-(phenylsulfonyl)ethylamino]-2-oxo-1-*p*-tolylethyl Acetate (3m): White solid (259 mg, 90%); m.p. 130.3–131.0 °C. ¹H



NMR (400 MHz, CDCl₃): δ = 7.98 (d, J = 7.9 Hz, 2 H), 7.84–7.20 (m, 7 H), 6.90 (t, J = 5.8 Hz, 1 H), 6.15 (s, 1 H), 4.33–4.18 (m, 2 H), 2.37 (s, 3 H), 2.23 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 169.2, 169.1, 139.2, 136.0, 132.0, 131.6, 130.8, 129.6, 129.5, 127.4, 120.3 (t, ${}^{1}J_{C,F}$ = 281.1 Hz), 75.2, 38.4 (t, ${}^{2}J_{C,F}$ = 25.3 Hz), 21.2, 20.9 ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = -107.1 (dt, $J_{F,F}$ = 234.9 Hz, $J_{H,F}$ = 12.3 Hz), -107.9 (dt, $J_{F,F}$ = 234.7 Hz, $J_{H,F}$ = 12.2 Hz) ppm.

2-[2,2-Difluoro-2-(phenylsulfonyl)ethylamino]-1-(4-fluorophenyl)-2oxoethyl Acetate (3n): White solid (242 mg, 91%); m.p. 100.1– 101.3 °C. ¹H NMR (400 MHz, CDCl₃): δ = 7.98 (d, *J* = 7.8 Hz, 2 H), 7.84–7.06 (m, 7 H), 7.00 (t, *J* = 5.8 Hz, 1 H), 6.16 (s, 1 H), 4.33– 4.18 (m, 2 H), 2.24 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 169.1, 168.8, 163.1 (d, ¹*J*_{C,F} = 248.3 Hz), 136.0, 131.5, 130.9 (d, ^{4'}*J*_{C,F} = 3.1 Hz), 130.7, 129.6, 129.4 (d, ^{3'}*J*_{C,F} = 8.6 Hz), 120.2 (t, ¹*J*_{C,F} = 289.7 Hz), 115.8 (d, ^{2'}*J*_{C,F} = 21.8 Hz), 74.6, 38.4 (t, ²*J*_{C,F} = 25.6 Hz), 20.9 ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = -107.1 (dt, *J*_{E,F} = 234.5 Hz, *J*_{H,F} = 12.3 Hz), -108.0 (dt, *J*_{E,F} = 235.1 Hz, *J*_{H,F} = 12.6 Hz) ppm.

General Procedure for the Synthesis of Compounds 4a–n: A buffer solution (8 M) of HOAc/NaOAc (1:1, 4 mL) was added to sulfone compounds 3a-n (0.5 mmol) in DMF (dimethylformamide) at room temp. Magnesium turnings (7.5 mmol) were added in portions. The reaction mixture was stirred for 3–6 h (TLC), and then water was added. The solution was extracted with Et₂O, and the combined organic phases were washed with a saturated solution of NaHCO₃ and brine and then dried with Na₂SO₄. After the removal of solvent, the crude product was purified by silica gel column chromatography to give products **4a–n**.

2-(2,2-Difluoroethylamino)-2-oxo-1-phenylethyl Benzoate (4a): White solid (145 mg, 91%); m.p. 118.0–119.2 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.12 (d, *J* = 7.8 Hz, 2 H), 7.66–7.39 (m, 8 H), 6.51 (t, *J* = 6.0 Hz, 1 H), 6.39 (s, 1 H), 5.88 (tt, ¹*J* = 55.9 Hz, ²*J* = 3.8 Hz, 1 H), 3.78–3.64 (m, 2 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 164.4, 160.2, 130.3, 129.0, 125.1, 124.5, 124.3, 124.2, 123.9, 122.6, 108.5 (t, ¹*J*_{C,F} = 241.5 Hz), 71.1, 36.9 (t, ²*J*_{C,F} = 26.6 Hz) ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = –123.1 (dt, ¹*J* = 55.9 Hz, ²*J* = 14.7 Hz) ppm. HRMS (ESI): calcd. for C₁₇H₁₄F₂NO₃ [M – H]⁺ 318.0942; found 318.0943.

2-(2,2-Difluoroethylamino)-2-oxo-1-phenylethyl Acetate (4b): White solid (115 mg, 90%); m.p. 102.6–104.0 °C. ¹H NMR (400 MHz, CDCl₃): δ = 7.46–7.39 (m, 5 H), 6.52 (t, *J* = 6.0 Hz, 1 H), 6.12 (s, 1 H), 5.88 (tt, ¹*J* = 55.9 Hz, ²*J* = 4.0 Hz, 1 H), 3.72–3.63 (m, 2 H), 2.21 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 169.1, 169.0, 135.0, 129.3, 128.9, 127.4, 113.3 (t, ¹*J*_{C,F} = 241.4 Hz), 75.4, 41.5 (t, ²*J*_{C,F} = 26.5 Hz), 20.9 ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = –123.1 (dt, ¹*J* = 56.0 Hz, ²*J* = 14.6 Hz) ppm. HRMS (ESI): calcd. for C₁₂H₁₂F₂NO₃ [M – H]⁺ 256.0785; found 256.0787.

2-(2,2-Difluoroethylamino)-2-oxo-1-*p***-tolylethyl Benzoate (4c):** White solid (150 mg, 90%); m.p. 118.8–120.5 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.11 (d, *J* = 7.8 Hz, 2 H), 7.65–7.23 (m, 7 H), 6.53 (t, *J* = 6.0 Hz, 1 H), 6.34 (s, 1 H), 5.87 (tt, ¹*J* = 56.0 Hz, ²*J* = 4.0 Hz, 1 H), 3.77–3.59 (m, 2 H), 2.38 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 169.4, 165.0, 139.3, 133.8, 132.1, 129.9, 129.7, 129.1, 128.7, 127.4, 113.3 (t, ¹*J*_{C,F} = 241.7 Hz), 75.7, 41.6 (t, ²*J*_{C,F} = 26.7 Hz), 21.2 ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = -123.0 (dt, ¹*J* = 56.0 Hz, ²*J* = 14.6 Hz) ppm. HRMS (ESI): calcd. for C₁₈H₁₆F₂NO₃ [M – H]⁺ 332.1098; found 332.1095.

2-(2,2-Difluoroethylamino)-1-(3,4-dimethoxyphenyl)-2-oxoethyl Benzoate (4d): White solid (169 mg, 89%); m.p. 151.8–152.8 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.10 (d, *J* = 7.7 Hz, 2 H), 7.65–6.88 (m, 6 H), 6.51 (t, J = 5.8 Hz, 1 H), 6.32 (s, 1 H), 5.89 (tt, ${}^{1}J = 55.9$ Hz, ${}^{2}J = 3.5$ Hz, 1 H), 3.91 (s, 3 H), 3.89 (s, 3 H), 3.84–3.62 (m, 2 H) ppm. 13 C NMR (100 MHz, CDCl₃): $\delta = 169.4$, 165.1, 149.9, 149.3, 133.8, 129.8, 129.1, 128.7, 127.4, 120.3, 113.3 (t, ${}^{1}J_{C,F} = 241.5$ Hz), 111.2, 110.7, 75.7, 56.0, 55.9, 41.6 (t, ${}^{2}J_{C,F} = 26.3$ Hz) ppm. 19 F NMR (376 MHz, CDCl₃): $\delta = -123.0$ (dtd, ${}^{1}J = 55.9$ Hz, ${}^{2}J = 12.5$ Hz, ${}^{2}J = 4.5$ Hz) ppm. HRMS (ESI): calcd. for C₁₉H₁₈F₂NO₅ [M - H]⁺ 378.1153; found 378.1152.

2-(2,2-Difluoroethylamino)-1-(4-fluorophenyl)-2-oxoethyl Benzoate (4e): White solid (150 mg, 89%); m.p. 141.2–142.5 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.10 (d, J = 7.3 Hz, 2 H), 7.67–7.09 (m, 7 H), 6.59 (t, J = 5.7 Hz, 1 H), 6.36 (s, 1 H), 5.89 (tt, ¹J = 55.8 Hz, ²J = 3.9 Hz, 1 H), 3.79–3.64 (m, 2 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 169.1, 164.9, 163.2 (d, ^{1'}J_{C,F} = 248.6 Hz), 134.0, 130.9 (d, ^{4'}J_{C,F} = 3.0 Hz), 129.8, 129.4 (d, ^{3'}J_{C,F} = 8.3 Hz), 128.8, 128.7, 116.0 (d, ^{2'}J_{C,F} = 21.9 Hz), 113.2 (t, ¹J_{C,F} = 241.5 Hz), 75.1, 41.6 (t, ²J_{C,F} = 26.5 Hz) ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = –111.8 to –111.9 (m), –123.0 (dtd, ¹J = 55.8 Hz, ²J = 13.2 Hz, ²J = 3.0 Hz) ppm. HRMS (ESI): calcd. for C₁₇H₁₃F₃NO₃ [M – H]⁺ 336.0848; found 336.0845.

2-(2,2-Difluoroethylamino)-1-(3,4-difluorophenyl)-2-oxoethyl Benzoate (4f): White solid (161 mg, 91%); m.p. 109.6–111.3 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.11–8.08 (m, 2 H), 7.67–7.13 (m, 6 H), 6.70 (t, *J* = 5.9 Hz, 1 H), 6.58 (s, 1 H), 5.91 (tt, ¹*J* = 55.9 Hz, ²*J* = 4.1 Hz, 1 H), 3.83–3.65 (m, 2 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 168.0, 164.7, 150.6 (dd, ^{1'}*J*_{C,F} = 250.1 Hz, ^{2''}*J*_{C,F} = 13.0 Hz), 149.1 (dd, ^{1''}*J*_{C,F} = 251.2 Hz, ^{2'}*J*_{C,F} = 13.8 Hz), 134.0, 129.9, 128.8, 128.6, 125.0 (d, ^{3''}*J*_{C,F} = 10.3 Hz), 124.8, 124.6 (dd, ^{3'}*J*_{C,F} = 6.7 Hz, ^{4''}*J*_{C,F} = 4.7 Hz), 118.5 (d, ^{2'}*J*_{C,F} = 17.1 Hz), 113.2 (t, ¹*J*_{C,F} = 241.5 Hz), 70.4, 41.7 (t, ²*J*_{C,F} = 29.1 Hz) ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = -123.1 (ddd, ¹*J* = 55.9 Hz, ²*J* = 26.5 Hz, ³*J* = 14.4 Hz), -136.9 to -137.0 (m), -141.0 (dt, ¹*J* = 20.7 Hz, ²*J* = 6.6 Hz) ppm. HRMS (ESI): calcd. for C₁₇H₁₂F₄NO₃ [M – H]⁺

2-(2,2-Difluoroethylamino)-1-[3-fluoro-4-(trifluoromethyl)phenyl]-2oxoethyl Benzoate (4g): White solid (180 mg, 89%); m.p. 165.9– 167.8 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.12 (d, J = 7.4 Hz, 2 H), 7.71–7.38 (m, 6 H), 6.63 (t, J = 5.6 Hz, 1 H), 6.41 (s, 1 H), 5.90 (tt, ¹J = 55.9 Hz, ²J = 4.0 Hz, 1 H), 3.79–3.65 (m, 2 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 167.9, 164.5, 159.8 (d, ^{1'} $J_{C,F}$ = 257.3 Hz), 141.5, 134.3, 129.9, 128.9, 128.3, 127.8, 122.8 (d, ^{4'} $J_{C,F}$ = 3.6 Hz), 115.7 (d, ^{2'} $J_{C,F}$ = 22.2 Hz), 113.1 (t, ¹ $J_{C,F}$ = 241.7 Hz), 74.3, 41.7 (t, ² $J_{C,F}$ = 26.1 Hz) ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = -61.6 (d, J = 12.5 Hz), -112.6 to -112.8 (m), -123.2 (dt, ¹J = 55.7 Hz, ²J = 14.8 Hz) ppm. HRMS (ESI): calcd. for C₁₈H₁₂F₆NO₃ [M - H]⁺ 404.0721; found 404.0720.

1-(2,2-Difluoroethylamino)-1-oxo-3-phenylpropan-2-yl Benzoate (**4h**): White solid (150 mg, 90%); m.p. 134.0–135.5 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.01 (d, J = 7.7 Hz, 2 H), 7.64–7.24 (m, 8 H), 6.18 (t, J = 6.3 Hz, 1 H), 5.71 (tt, ¹J = 55.6 Hz, ²J = 4.2 Hz, 1 H), 5.69 (t, J = 5.5 Hz, 1 H), 3.68–3.51 (m, 2 H), 3.34 (d, J = 5.6 Hz, 2 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 169.8, 165.1, 135.4, 133.8, 129.8, 129.6, 128.9, 128.7, 128.5, 127.2, 113.3 (t, ¹ $J_{C,F}$ = 241.8 Hz), 74.6, 41.4 (t, ² $J_{C,F}$ = 26.7 Hz), 37.8 ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = –121.9 to –123.7 (m) ppm. HRMS (ESI): calcd. for C₁₈H₁₆F₂NO₃ [M – H]⁺ 332.1098; found 332.1096.

2-(2,2-Difluoroethylamino)-1-(4-methoxyphenyl)-2-oxoethyl Benzoate (4i): White solid (161 mg, 92%); m.p. 129.6–130.9 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.10 (d, *J* = 8.0 Hz, 2 H), 7.65–6.93 (m, 7 H), 6.55 (t, *J* = 5.5 Hz, 1 H), 6.33 (s, 1 H), 5.88 (tt, ¹*J* = 55.9 Hz, ²*J* = 4.0 Hz, 1 H), 3.83 (s, 3 H), 3.78–3.62 (m, 2 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 169.5, 165.1, 160.3, 133.7, 129.8, 129.1,

FULL PAPER

129.0, 128.7, 127.1, 114.4, 113.3 (t, ${}^{1}J_{C,F}$ = 241.5 Hz), 75.6, 55.3, 41.6 (t, ${}^{2}J_{C,F}$ = 26.6 Hz) ppm. 19 F NMR (376 MHz, CDCl₃): δ = -123.0 (dt, ${}^{1}J$ = 56.3 Hz, ${}^{2}J$ = 15.0 Hz) ppm. HRMS (ESI): calcd. for C₁₈H₁₆F₂NO₄ [M – H]⁺ 348.1047; found 348.1044.

2-(2,2-difluoroethylamino)-1-(3-fluoro-2-methylphenyl)-2-oxoethyl Benzoate (4j): White solid (158 mg, 90%); m.p. 79.4–81.2 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.10–8.08 (m, 2 H), 7.65–7.05 (m, 6 H), 6.75 (t, *J* = 5.9 Hz, 1 H), 6.61 (s, 1 H), 5.89 (tt, ¹*J* = 55.9 Hz, ²*J* = 4.0 Hz, 1 H), 3.76–3.60 (m, 2 H), 2.44 (d, *J* = 2.1 Hz, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 169.1, 164.9, 161.4 (d, ^{1'}*J*_{C,F} = 244.9 Hz), 136.0 (d, ^{5'}*J*_{C,F} = 4.2 Hz), 133.9, 129.8, 128.7, 128.4, 127.3 (d, ^{3'}*J*_{C,F} = 8.8 Hz), 124.8 (d, ^{2''}*J*_{C,F} = 17.4 Hz), 123.5 (d, ^{4''}*J*_{C,F} = 3.2 Hz), 116.1 (d, ^{2'}*J*_{C,F} = 23.4 Hz), 113.3 (t, ¹*J*_{C,F} = 241.5 Hz), 73.0 (d, ^{4''}*J*_{C,F} = 2.9 Hz), 41.6 (t, ²*J*_{C,F} = 26.4 Hz), 10.7 (d, ^{3''}*J*_{C,F} = 5.8 Hz) ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = –114.8 to –114.9 (m), –123.0 (dt, *J*₁ = 55.9 Hz, *J*₂ = 14.8 Hz) ppm. HRMS (ESI): calcd. for C₁₈H₁₅F₃NO₃ [M – H]⁺ 350.1004; found 350.1002.

2-(2,2-Difluoroethylamino)-2-oxo-1-*o***-tolylethyl Benzoate (4k):** White solid (150 mg, 90%); m.p. 99.1–100.8 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.10 (d, J = 7.3 Hz, 2 H), 7.65–7.26 (m, 7 H), 6.63 (s, 1 H), 6.50 (t, J = 6.0 Hz, 1 H), 5.89 (tt, ¹J = 55.9 Hz, ²J = 4.0 Hz, 1 H), 3.78–3.63 (m, 2 H), 2.55 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 169.4, 165.0, 137.3, 133.8, 133.6, 131.2, 129.9, 129.4, 129.0, 128.7, 127.8, 126.5, 113.3 (t, ¹ $J_{C,F}$ = 241.4 Hz), 73.5, 41.6 (t, ² $J_{C,F}$ = 26.6 Hz), 19.5 ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = –123.0 (dt, ¹J = 55.9 Hz, ²J = 14.8 Hz) ppm. HRMS (ESI): calcd. for C₁₈H₁₆F₂NO₃ [M – H]⁺ 332.1098; found 332.1099.

1-(3-Bromophenyl)-2-(2,2-difluoroethylamino)-2-oxoethyl Benzoate (41): White solid (177 mg, 89%); m.p. 92.7–93.8 °C. ¹H NMR (400 MHz, CDCl₃): δ = 8.11 (d, J = 7.6 Hz, 2 H), 7.70–7.28 (m, 7 H), 6.68 (t, J = 6.0 Hz, 1 H), 6.32 (s, 1 H), 5.87 (tt, ¹J = 55.8 Hz, ²J = 3.4 Hz, 1 H), 3.76–3.60 (m, 2 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 168.7, 164.8, 137.1, 134.0, 132.4, 130.5, 130.3, 129.9, 128.8, 127.4, 126.1, 122.9, 113.2 (t, ¹ $J_{C,F}$ = 241.6 Hz), 74.9, 41.6 (t, ² $J_{C,F}$ = 26.4 Hz) ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = –123.0 (dt, ¹J = 55.8 Hz, ²J = 14.7 Hz) ppm. HRMS (ESI): calcd. for C₁₇H₁₃BrF₂NO₃ [M – H]⁺ 396.0047; found 396.0048.

2-(2,2-Difluoroethylamino)-2-oxo-1-*p***-tolylethyl Acetate (4m):** White solid (122 mg, 90%); m.p. 97.1–98.5 °C. ¹H NMR (400 MHz, CDCl₃): δ = 7.34–7.20 (m, 4 H), 6.46 (t, *J* = 5.8 Hz, 1 H), 6.09 (s, 1 H), 5.85 (tt, ¹*J* = 55.9 Hz, ²*J* = 4.1 Hz, 1 H), 3.73–3.62 (m, 2 H), 2.37 (s, 3 H), 2.20 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 169.3, 169.2, 139.3, 132.1, 129.6, 127.4, 113.3 (t, ¹*J*_{C,F} = 241.4 Hz), 75.3, 41.6 (t, ²*J*_{C,F} = 26.6 Hz), 21.2, 20.9 ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = -123.0 (dt, ¹*J* = 55.9 Hz, ²*J* = 14.7 Hz) ppm. HRMS (ESI): calcd. for C₁₃H₁₄F₂NO₃ [M – H]⁺ 270.0942; found 270.0940.

2-(2,2-Difluoroethylamino)-1-(4-fluorophenyl)-2-oxoethyl Acetate (4n): White solid (126 mg, 92%); m.p. 116.8–118.0 °C. ¹H NMR (400 MHz, CDCl₃): δ = 7.44–7.05 (m, 4 H), 6.63 (t, *J* = 5.8 Hz, 1 H), 6.09 (s, 1 H), 5.85 (tt, ¹*J* = 55.8 Hz, ²*J* = 3.9 Hz, 1 H), 3.73–3.61 (m, 2 H), 2.20 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 169.1, 169.0, 163.1 (d, ^{1'}*J*_{C,F} = 248.5 Hz), 131.0 (d, ^{4'}*J*_{C,F} = 3.4 Hz), 129.4 (d, ^{3'}*J*_{C,F} = 8.5 Hz), 115.9 (d, ^{2'}*J*_{C,F} = 21.9 Hz), 113.3 (t, ¹*J*_{C,F} = 241.4 Hz), 74.6, 41.5 (t, ²*J*_{C,F} = 26.2 Hz), 20.9 ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = -111.9 to -112.0 (m), -123.1 (dt, ¹*J* = 55.8 Hz, ²*J* = 14.9 Hz) ppm. HRMS (ESI): calcd. for C₁₂H₁₁F₃NO₃ [M – H]⁺ 274.0691; found 274.0695.

General Procedure for the Synthesis of Compounds 5a–c: To a solution of **2a–d** (0.5 mmol) in dry toluene (1 mL) was added Bu₃SnH (870 mg, 1.5 mmol) under an argon atmosphere. Deoxygenation

was continued for 5 min. AIBN (8 mg, 0.05 mmol) was added, and the solution was heated at reflux for 24 h (TLC). The mixture was concentrated under reduced pressure, and the residue was dissolved in EtOAc (5 mL). The solution was stirred overnight in the presence of KF/H₂O (15 mg/0.15 mL) and then extracted with EtOAc. The organic phase was washed successively with water and brine and then dried with anhydrous Na₂SO₄. After solvent removal, the crude products were purified by chromatography to give deacylation compounds **5a–c**.

N-[2,2-Difluoro-2-(phenylthio)ethyl]-2-hydroxy-2-phenylacetamide (5a): White solid (108 mg, 67%); m.p. 74.1–75.5 °C. ¹H NMR (400 MHz, CDCl₃): δ = 7.57 (d, *J* = 7.2 Hz, 2 H), 7.45–7.34 (m, 8 H), 6.94 (t, *J* = 5.6 Hz, 1 H), 5.04 (s, 1 H), 3.91–3.71 (m, 2 H), 3.61 (s, 1 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 172.3, 138.9, 136.4, 130.2, 129.3, 128.9, 128.8, 127.4 (t, ¹*J*_{C,F} = 279.9 Hz), 127.0, 125.7, 74.4, 44.5 (t, ²*J*_{C,F} = 29.0 Hz) ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = -79.0 (dt, *J*_{F,F} = 213.0 Hz, *J*_{H,F} = 12.4 Hz), -79.6 (dt, *J*_{F,F} = 213.5 Hz, *J*_{H,F} = 12.5 Hz) ppm. HRMS (ESI): calcd. for C₁₆H₁₅F₂NO₂SNa [M + Na]⁺ 346.0689; found 346.0689.

N-[2,2-Difluoro-2-(phenylthio)ethyl]-2-hydroxy-2-*p*-tolylacetamide (5b): White solid (114 mg, 68%); m.p. 98.0–99.4 °C. ¹H NMR (400 MHz, CDCl₃): δ = 7.59 (d, *J* = 7.6 Hz, 2 H), 7.48–7.18 (m, 7 H), 6.99 (t, *J* = 5.7 Hz, 1 H), 5.00 (s, 1 H), 3.92–3.70 (m, 2 H), 3.88 (s, 1 H), 2.37 (s, 3 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 172.8, 138.6, 136.4, 136.1, 130.2, 129.5, 129.3, 128.2, 127.5 (t, ¹*J*_{C,F} = 279.9 Hz), 126.9, 74.2, 44.5 (t, ²*J*_{C,F} = 28.9 Hz), 21.2 ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = −78.8 (dt, *J*_{F,F} = 212.7 Hz, *J*_{H,F} = 12.4 Hz), −79.5 (dt, *J*_{F,F} = 212.7 Hz, *J*_{H,F} = 12.6 Hz) ppm. HRMS (ESI): calcd. for C₁₇H₁₇F₂NO₂SNa [M + Na]⁺ 360.0846; found 360.0844.

N-[2,2-Difluoro-2-(phenylthio)ethyl]-2-(3,4-dimethoxyphenyl)-2-hydroxyacetamide (5c): White solid (138 mg, 57%); m.p. 120.5– 121.7 °C. ¹H NMR (400 MHz, CDCl₃): δ = 7.57 (d, *J* = 7.6 Hz, 2 H), 7.47–6.85 (m, 6 H), 6.74 (t, *J* = 6.0 Hz, 1 H), 5.05 (s, 1 H), 3.99–3.73 (m, 2 H), 3.88 (s, 3 H), 3.86 (s, 3 H), 3.48 (s, 1 H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 172.5, 149.5, 149.4, 136.3, 131.4, 130.2, 129.3, 127.4 (t, ¹*J*_{C,F} = 279.9 Hz), 125.7, 119.8, 111.2, 109.7, 74.2, 56.0, 55.9, 44.5 (t, ²*J*_{C,F} = 28.9 Hz) ppm. ¹⁹F NMR (376 MHz, CDCl₃): δ = -79.1 (dt, *J*_{F,F} = 213.0 Hz, *J*_{H,F} = 12.3 Hz), -79.7 (dt, *J*_{F,F} = 213.2 Hz, *J*_{H,F} = 12.6 Hz) ppm. HRMS (ESI): calcd. for C₁₈H₁₉F₂NO₄SNa [M + Na]⁺ 406.0901; found 406.0899.

Supporting Information (see footnote on the first page of this article): Copies of the ¹H NMR, ¹³C NMR, ¹⁹F NMR spectra and high-resolution mass spectra.

Acknowledgments

We are grateful for financial support from the National Natural Science Foundation of China (Grant No. 21072057), the National Basic Research Program of China (973 Program, 2010CB126101), and the Key Project in the National Science & Technology Pillar Program of China in the twelfth five-year plan period (2011BAE06B05).

- [1] A. Dömling, I. Ugi, Angew. Chem. 2000, 112, 3300; Angew. Chem. Int. Ed. 2000, 39, 3168–3210.
- [2] a) K. Nagaoka, M. Matsumoto, J. Oono, K. Yokoi, S. Ishizeki,
 T. Nakashima, J. Antibiot. 1986, 39, 1527–1532; b) C. Liu,
 G. T. Kelly, C. M. H. Watanabe, Org. Lett. 2006, 8, 1065–1068.
- [3] H. Yanagita, E. Urano, K. Matsumoto, R. Ichikawa, Y. Takaesu, M. Ogata, T. Murakami, H. Wu, J. Chiba, J. Komano, T. Hoshino, *Bioorg. Med. Chem.* 2011, 19, 816–825.



- [4] D. Song, J. Major, J. Hutzler, T. W. Newton, A. Vescovi, R. Reinhard, B. Sievernich, C. Zagar, E. Kibler, R. Niggeweg, T. Kühn, M. Witschel, W. K. Moberg, R. L. Parra, T. Qu, F. Stelzer, A. Van Der Kloet, T. Seitz, T. Ehrhardt, K. Kreuz, K. Groβmann, A. A. Michrowska-pianowska, A. Simon, R. R. Evans, E. Hupe, K. Reinhard, M. Bergtold, S. N. E. Kolle, S. Tersch, WO 2011073143A1, **2007**.
- [5] a) P. Politzer, J. Am. Chem. Soc. 1969, 91, 6235–6237; b) K. Müller, C. Faeh, F. Diederich, Science 2007, 317, 1881–1886;
 c) J. P. Bégué, D. Bonnet-Delpon, J. Fluorine Chem. 2006, 127, 992–1012; d) W. K. Hagmann, J. Med. Chem. 2008, 51, 4359–4369; e) H. Meng, K. Kumar, J. Am. Chem. Soc. 2007, 129, 15615–15622; f) C. Jäckel, B. Koksch, Eur. J. Org. Chem. 2005, 4483–4503; g) V. P. Kukhar, A. E. Sorochinsky, V. A. Soloshonok, Future Med. Chem. 2009, 1, 793–819; h) L. Hunter, Beilstein J. Org. Chem. 2010, 6, No. 38, DOI: 10.3762/ bjoc.6.38.
- [6] a) A. V. Gulevich, I. V. Shpilevaya, V. G. Nenajdenko, *Eur. J. Org. Chem.* 2009, 3801–3808; b) K. Burger, K. Mütze, W. Hollweck, B. Koksch, *Tetrahedron* 1998, 54, 5915–5928.
- [7] a) Y. Liu, T. Shi, F. Zhou, X. Zhao, X. Wang, J. Zhou, Org. Lett. 2011, 13, 3826–3829; b) M. Ilies, L. D. Costanzo, D. P. Dowling, K. J. Thorn, D. W. Christianson, J. Med. Chem. 2011, 54, 5432–5443; c) S. B. Ferreira, M. S. Cost, N. Boechat, R. J. S. Bezerra, M. S. Genestra, M. M. Canto-Cavalheiro, W. B. Kover, V. F. Ferreira, Eur. J. Med. Chem. 2007, 42, 1388–1395; d) I. Ojima, S. Lin, J. C. Slater, T. Wang, P. Pera, R. J. Bernacki, C. Ferlin, G. Scambia, Bioorg. Med. Chem. 2000, 8, 1619–1628; e) Y. Takumi, N. Masao, A. Sohei, H. Ryo, H. Manabu, K. Shigefumi, J. Pestic. Sci. 2011, 36, 212–220; f) W. F. Goure, K. L. Leschinsky, S. J. Wratten, J. P. Chupp, J. Agric. Food Chem. 1991, 39, 981–986.

- [8] J. A. Erickson, J. I. McLoughlin, J. Org. Chem. 1995, 60, 1626– 1631.
- [9] a) L. Shen, S. Cao, J. Wu, H. Li, J. Yu, J. Zhang, M. Wu, X. Qian, *Tetrahedron Lett.* 2010, *51*, 4866–4869; b) H. Li, J. Yu, S. Cao, L. Shen, M. Wu, J. Cheng, X. Qian, *Sci. China, Ser. B* 2010, *53*, 1509–1513; c) M. Wu, J. Yu, W. Zhao, J. Wu, S. Cao, *J. Fluorine Chem.* 2011, *132*, 155–159.
- [10] a) J. Wu, S. Cao, N. Liu, L. Shen, J. Yu, J. Zhang, H. Li, X. Qian, Org. Biomol. Chem. 2010, 8, 2386–2391; b) J. Zhang, J. Wu, L. Shen, G. Jin, S. Cao, Adv. Synth. Catal. 2011, 353, 580–584; c) J. Wu, H. Li, S. Cao, Beilstein J. Org. Chem. 2011, 7, 1070–1074.
- [11] A. Dömling, Chem. Rev. 2006, 106, 17-89.
- [12] a) Y. Li, J. Hu, Angew. Chem. 2007, 119, 2541; Angew. Chem. Int. Ed. 2007, 46, 2489–2492; b) V. Reutrakul, T. Thongpaisanwong, P. Tuchinda, C. Kuhakarn, M. Pohmakotr, J. Org. Chem. 2004, 69, 6913–6915; c) M. Pohmakotr, D. Panichakul, P. Tuchinda, V. Reutrakul, Tetrahedron 2007, 63, 9429–9436.
- [13] G. K. S. Prakash, J. Hu, Acc. Chem. Res. 2007, 40, 921-930.
- [14] S. Chen, R. F. Horvath, J. Joglar, M. J. Fisher, S. J. Danishefsky, J. Org. Chem. 1991, 56, 5834–5845.
- [15] G. E. Keck, K. A. Savin, M. A. Weglarz, J. Org. Chem. 1995, 60, 3194–3204.
- [16] E. Lee, C. S. Pak, G. H. Lee, E. B. Choi, *Tetrahedron Lett.* 1993, 34, 4541–4542.
- [17] C. Ni, J. Hu, Tetrahedron Lett. 2005, 46, 8273-8277.
- [18] a) S. Mirilashvili, N. Chasid-Rubinstein, A. Albeck, *Eur. J. Org. Chem.* 2008, 3461–3464; b) C. Tsukano, M. Ebine, M. Sasaki, *J. Am. Chem. Soc.* 2005, *127*, 4326–4335.

Received: October 18, 2011 Published Online: January 23, 2012